<DOC>
	<DOCNO>NCT02652468</DOCNO>
	<brief_summary>To determine engraftment neutrophil platelets 28 day follow alpha/beta T-cell CD19 cell depletion use HLA haploidentical donor peripheral blood stem cell transplant relapse lymphoma . Assess incidence acute GVHD ( Graft versus Host Disease ) , chronic GVHD , graft failure rate , treatment related mortality rate , progression free survival overall survival patient . The stem cell product process use investigational Miltenyi cell selection device/system remove alpha/beta T-cells CD19+ cell , immune system cell likely cause GVHD .</brief_summary>
	<brief_title>TCR-α/β CD19 Depleted Stem Cell Grafts From Haplo Donors HSCT Relapsed Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>Patients must meet one follow disease criterion : Relapsed/refractory Hodgkin lymphoma autologous stem cell transplantation Relapsed/refractory Hodgkin lymphoma , deem ineligible autologous stem cell transplantation due refractory disease Relapsed/refractory diffuse large B cell lymphoma autologous stem cell transplantation ( history transform lymphoma acceptable ) Relapsed/refractory diffuse large B cell lymphoma , deem ineligible autologous stem cell transplantation due refractory disease ( history transform lymphoma acceptable ) Relapsed/refractory T cell lymphoma relapse least 1 prior line therapy Relapsed/refractory follicular lymphoma relapse least 1 prior line therapy Relapsed/refractory mantle cell lymphoma relapse least 1 prior line therapy Relapsed/refractory small lymphocytic lymphoma/chronic lymphocytic leukemia relapse least 1 prior line therapy Karnofsky score 60 % good ( `` Requires occasional assistance , able care his/her need '' ) . Pulmonary : DLCO ( correct hemoglobin ) &gt; 40 % ; FEV1 &gt; 50 % Cardiac : EF ≥ 50 % uncontrolled angina , symptomatic ventricular arrhythmia , ECG evidence active ischemia Renal : estimate GFR MDRD formula &gt; 40 mL/min/1.73m2 Women child bear potential must negative serum urine pregnancy test within 14 day prior study registration agree use adequate birth control study treatment . A female childbearing potential ( FCBP ) sexually mature female : 1 ) undergone hysterectomy bilateral oophorectomy ; 2 ) naturally postmenopausal least 24 consecutive month ( i.e. , menses time precede 24 consecutive month ) . Voluntary write consent Active CNS lymphoma within two week registration . Patients history CNS involvement must adequate treatment define least two negative spinal fluid assessment separate least one week . ( Otherwise LP require clinical suspicion evidence CNS involvement . ) Patients receive cranial radiation therapy must still eligible receive total lymphoid irradiation 7 Gy . New active infection determine fever , unexplained pulmonary infiltrate sinusitis radiographic assessment . Infections diagnose within 4 week registration must determine control resolve prior treatment . Presence HIV , active hepatitis A , B , C infection Allergy hypersensitivity agent use within treatment protocol . For indolent lymphoma histology ( follicular lymphoma , SLL/CLL ) mantle cell lymphoma , patient HLAmatched sibling , would eligible donor , available . Vulnerable population group , i.e. , prisoner , lack consent capacity , nonEnglish speaking , illiterate , pregnant female .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>